Publications by authors named "H Ichiyasu"
A 59-year-old woman presented with multiple mediastinal masses 6 months after post-thymectomy for type B2 thymoma. A diagnosis of small-cell carcinoma (SmCC) via a computed tomography-guided biopsy and fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography revealed no primary lesions outside the anterior mediastinum. The pathologically reevaluated post-thymectomy specimen showed no neuroendocrine differentiation.
View Article and Find Full Text PDFArticle Synopsis
- F-FDG PET/CT is commonly used to monitor non-small cell lung cancer (NSCLC), but its impact on the effectiveness of osimertinib treatment for patients with EGFR mutations is not well understood.
- A study of 74 patients found that those with a higher maximum standardized uptake value (SUVmax) in their primary tumors had shorter progression-free survival (PFS) compared to those with lower SUVmax, although overall survival (OS) remained similar.
- High SUVmax was identified as an independent negative predictor for PFS in patients receiving osimertinib, indicating its potential as a useful marker for treatment outcomes.
Article Synopsis
- AE-IIPs are serious conditions linked to poor outcomes in patients with idiopathic interstitial pneumonias.
- A unique case study highlights that F-FDG PET/CT imaging was able to detect signs of AE-IIPs in a lung cancer patient just 18 days after a bronchoscopy, prior to respiratory failure.
- This report is the first to examine F-FDG PET/CT findings during the early stages of AE-IIPs, potentially enhancing our understanding of the disease’s mechanisms.
Article Synopsis
- * Immune checkpoint inhibitors (ICIs), like pembrolizumab, typically have limited responses in these cases but can be beneficial after osimertinib fails.
- * A reported patient showed a lasting positive response to pembrolizumab after initially progressing on osimertinib, indicating that ICIs could be a valuable treatment option for early progressors.
Pulmonary tumor embolisms (PTEs) are primarily caused by adenocarcinoma. However, only a few cases of oropharyngeal carcinoma have been reported. We herein report a 47-year-old man who presented with a fever, cough, and dyspnea 6 months after treatment for stage II oropharyngeal carcinoma.
View Article and Find Full Text PDF